Advertisement
Ambulatory and Office Urology| Volume 79, ISSUE 6, P1224-1225, June 2012

Editorial Comment

      In the spectrum of BPS, IC is still a pathophysiologic enigma and its treatment empirical. Simplistically, it is considered to be result of a multifactorial cascade of events that culminate into an imbalance of the damage-repair process of the urothelium, leading to deficiency of the GAG layer and the resulting symptoms. Various oral and intravesical GAG analogs have been in clinical use, most notably pentosan polysulphate (oral), hyaluronic acid (intravesical), and heparin (intravesical). Of these, only pentosan polysulphate has been subject to comprehensive scrutiny through randomized placebo-controlled trials, the results of which have been published in peer-reviewed reports. Its efficacy has been reported to be moderate at best.
      • Davis E.L.
      • El Khoudary S.R.
      • Talbott E.O.
      • et al.
      Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial.
      In this regard, the authors must be complimented for conducting a very well-designed, double-blind, placebo-controlled trial on another GAG analog chondroitin sulphate and reaffirming the inefficacy of this medication. Therefore, despite the pathologic proof of GAG deficiency, none of the available GAG analogs have proved to have robust activity in controlling the symptoms.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Davis E.L.
        • El Khoudary S.R.
        • Talbott E.O.
        • et al.
        Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial.
        J Urol. 2008; 179: 177-185
        • Keay S.K.
        • Zhang C.
        • Shoenfelt J.
        • et al.
        Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor as urine markers for interstitial cystitis.
        Urology. 2001; 57: 9-14
        • Keay S.
        • Kaczmarek P.
        • Zhang C.
        • et al.
        Normalization of proliferation and tight junction formation in bladder epithelial cells from patients with interstitial cystitis/painful bladder syndrome by D-proline and D-pipecolic acid derivatives of antiproliferative factor.
        Chem Biol Drug Des. 2011; 77: 421-430
        • Zhang Q.
        • Shen X.
        • Zhou Z.
        • et al.
        Decreased nanobacteria levels and symptoms of nanobacteria-associated interstitial cystitis/painful bladder syndrome after tetracycline treatment.
        Int Urogynecol J. 2010; 21: 103-109
        • Canter M.P.
        • Graham C.A.
        • Heit M.H.
        • et al.
        Proteomic techniques identify urine proteins that differentiate patients with interstitial cystitis from asymptomatic control subjects.
        Am J Obstet Gynecol. 2008; 198: 553.e1-553.e6

      Linked Article